NeuroMetrix, Inc. (Nasdaq: NURO, NUROW) today announced that Dr. Xuan Kong, SVP, Research and Intellectual Property, will present the Company’s DPNCheck® technology at the 5th Annual Diabetic Peripheral Neuropathy Fellowship for Chinese Physicians at the University of Sheffield which runs from October 10 to October 21.
The fellowship is organized by Professor Solomon Tesfaye, M.D., FRCP, a world-renown expert in diabetic neuropathies. It is a training fellowship for Chinese professors who are key opinion leaders in diabetic neuropathy and are selected by the Chinese Diabetes Society from all over China. The intensive 2-week fellowship has interactive, hands-on workshops; and contributions from neuropathy experts from the UK, Europe and the USA, and covers all aspects of diabetic neuropathies.
“We are honored to have been invited to Sheffield to discuss our DPNCheck technology with diabetes thought leaders from China,” said Shai N. Gozani, M.D., Ph.D., President and CEO of NeuroMetrix. “The timing this year is particularly relevant as we are gearing up to launch DPNCheck in China before the end of the year.”
DPNCheck is a rapid, accurate and quantitative point-of-care test to detect diabetic peripheral neuropathy, or DPN, at an early stage allowing physicians to select appropriate treatment. DPN is the most common complication of diabetes, affecting over half of people with diabetes. It causes significant morbidity including pain, increased risk of falling in the elderly, and is the primary trigger for diabetic foot ulcers which may require lower extremity amputations. DPNCheck is marketed in the U.S. to Medicare Advantage providers for profiling their patient population as well as guiding treatment. It is marketed in Japan by Omron Healthcare and in Mexico by Scienta Pharma. For product information visit DPNCheck.com.
NeuroMetrix is a commercial stage, innovation driven healthcare company combining bioelectrical and digital medicine to address chronic health conditions including chronic pain, sleep disorders, and diabetes. The company's lead product is Quell®, an over-the-counter wearable therapeutic device for chronic pain. Quell is integrated into a digital health platform that helps patients optimize their therapy and decrease the impact of chronic pain on their quality of life. The company also markets DPNCheck®, a rapid point-of-care test for diabetic neuropathy, which is the most common long-term complication of Type 2 diabetes. The company maintains an active research effort and has several pipeline programs, including a therapeutic device for restless leg syndrome. The company is located in Waltham, Massachusetts and was founded as a spinoff from the Harvard-MIT Division of Health Sciences and Technology in 1996. For more information, please visit www.NeuroMetrix.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161006006182/en/Business Wire
Last updated on: 06/10/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.